| scholarly article | Q13442814 |
| P50 | author | Henry Leonidas Gómez | Q43270076 |
| Miguel Martin | Q56550967 | ||
| Christos M. Hatzis | Q57009658 | ||
| Ana Lluch | Q67755317 | ||
| Gabriel N Hortobagyi | Q88225186 | ||
| Joyce O'Shaughnessy | Q88307619 | ||
| Kelly K Hunt | Q90520703 | ||
| Laura Esserman | Q91960202 | ||
| P2093 | author name string | Wei Yang | |
| Lajos Pusztai | |||
| Yun Wu | |||
| W Fraser Symmans | |||
| Hongkun Wang | |||
| Vicente Valero | |||
| Naoto T Ueno | |||
| Angela DeMichele | |||
| Yun Gong | |||
| Jaime Ferrer-Lozano | |||
| Daniel J Booser | |||
| Nuhad Ibrahim | |||
| Tatiana Vidaurre | |||
| Eleni Andreopoulou | |||
| José Cotrina | |||
| Meredith Buxton | |||
| Frankie Holmes | |||
| Arlene Nazario | |||
| Richard Dyer | |||
| Rebekah Hubbard | |||
| Eduardo Souchon | |||
| J Ignacio Chacón | |||
| P2860 | cites work | Retracted: An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer | Q21144332 |
| Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial | Q24597456 | ||
| Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer | Q29615523 | ||
| Supervised risk predictor of breast cancer based on intrinsic subtypes | Q29617404 | ||
| Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer | Q30433483 | ||
| Univariate shrinkage in the cox model for high dimensional data | Q33437869 | ||
| Effect of training-sample size and classification difficulty on the accuracy of genomic predictors | Q33892880 | ||
| Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer | Q33989876 | ||
| Genomic index of sensitivity to endocrine therapy for breast cancer. | Q34193932 | ||
| Genomic signatures to guide the use of chemotherapeutics. | Q34576027 | ||
| Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial | Q34714877 | ||
| Gene-expression signatures in breast cancer | Q34948421 | ||
| ??? | Q27005551 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| A pathologist's perspective on emerging genomic tests for breast cancer | Q36826364 | ||
| Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features | Q37125093 | ||
| Genomic grade index is associated with response to chemotherapy in patients with breast cancer | Q37278382 | ||
| Weekly paclitaxel in the adjuvant treatment of breast cancer. | Q37346811 | ||
| A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program | Q42429916 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade | Q42510471 | ||
| Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer | Q44541885 | ||
| Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series | Q44811326 | ||
| Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer | Q44891164 | ||
| The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer | Q46123139 | ||
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer | Q46771645 | ||
| Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. | Q50666942 | ||
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. | Q51935846 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma | Q73472938 | ||
| Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 | Q77438388 | ||
| Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study | Q79847215 | ||
| Quantifying and comparing the accuracy of binary biomarkers when predicting a failure time outcome | Q80040837 | ||
| Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system | Q80358653 | ||
| Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27 | Q83137320 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 1873-1881 | |
| P577 | publication date | 2011-05-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer | |
| P478 | volume | 305 |
| Q28730572 | 'Omic approaches to preventing or managing metastatic breast cancer |
| Q51039907 | A 20-gene signature in predicting the chemoresistance of breast cancer to taxane-based chemotherapy. |
| Q90505119 | A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer |
| Q37741425 | A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy |
| Q43265075 | A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer |
| Q39141610 | A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. |
| Q90754426 | A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence |
| Q91744969 | A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy |
| Q92713898 | A Stemness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer |
| Q47601795 | A Systems Biology Approach Provides Deeper Insights into Differentially Expressed Genes in Taxane-Anthracycline Chemoresistant and Non-Resistant Breast Cancers |
| Q35106947 | A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples |
| Q30587056 | A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer |
| Q33914753 | A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. |
| Q36268645 | A network-based pathway-expanding approach for pathway analysis. |
| Q40090503 | A novel FOXA1/ESR1 interacting pathway: A study of Oncomine™ breast cancer microarrays |
| Q92151499 | A plea for taking all available clinical information into account when assessing the predictive value of omics data |
| Q34105960 | A program to identify prognostic and predictive gene signatures |
| Q44615442 | A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation |
| Q34266467 | A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy |
| Q35886083 | A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer |
| Q97542122 | AITL: Adversarial Inductive Transfer Learning with input and output space adaptation for pharmacogenomics |
| Q38713230 | AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program. |
| Q36562382 | ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer |
| Q35655334 | APC selectively mediates response to chemotherapeutic agents in breast cancer |
| Q30747169 | Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples |
| Q34359310 | Age-specific changes in intrinsic breast cancer subtypes: a focus on older women |
| Q37472659 | Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer |
| Q30487036 | An 18-gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer |
| Q58790272 | An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer |
| Q37689702 | An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk |
| Q39308117 | Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors |
| Q37131923 | Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion |
| Q39034717 | Angiopoietin pathway gene expression associated with poor breast cancer survival |
| Q37374438 | Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer |
| Q37708928 | Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis |
| Q45952985 | Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. |
| Q90018363 | Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer |
| Q89340939 | Autophagic reliance promotes metabolic reprogramming in oncogenic KRAS-driven tumorigenesis |
| Q35853244 | Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity |
| Q91713543 | BCL11A Promotes the Progression of Laryngeal Squamous Cell Carcinoma |
| Q35114304 | BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells |
| Q90173918 | Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications |
| Q38893074 | Biology and Management of Patients With Triple-Negative Breast Cancer |
| Q54337477 | Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. |
| Q38833708 | Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation |
| Q104693489 | Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox |
| Q37689788 | BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome |
| Q90568296 | CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer |
| Q35892362 | CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. |
| Q37352596 | Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer? |
| Q42182888 | Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy |
| Q99571268 | Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments |
| Q45962835 | Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. |
| Q50001777 | Chromosomal instability drives metastasis through a cytosolic DNA response |
| Q34339847 | Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization |
| Q29248640 | Clinical and multiple gene expression variables in survival analysis of breast cancer: Analysis with the hypertabastic survival model |
| Q42501422 | Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer |
| Q35671323 | Co-modulation analysis of gene regulation in breast cancer reveals complex interplay between ESR1 and ERBB2 genes |
| Q36545800 | Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells |
| Q31011613 | Comparative study of joint analysis of microarray gene expression data in survival prediction and risk assessment of breast cancer patients |
| Q39677632 | Comparing continuous and discrete analyses of breast cancer survival information |
| Q46083625 | Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients |
| Q47145727 | Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer |
| Q36584124 | Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. |
| Q40931694 | Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer |
| Q64116725 | Correlation-adjusted regression survival scores for high-dimensional variable selection |
| Q35658975 | Cripto-1 as a novel therapeutic target for triple negative breast cancer |
| Q36195450 | Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib |
| Q33849252 | DACH1 suppresses breast cancer as a negative regulator of CD44. |
| Q37686041 | DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms |
| Q92063315 | DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling |
| Q35905370 | DNA Methylation Affects the SP1-regulated Transcription of FOXF2 in Breast Cancer Cells |
| Q30707752 | Database integration of 4923 publicly-available samples of breast cancer molecular and clinical data |
| Q38859166 | Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer |
| Q35606889 | Development and validation of a novel platform-independent metastasis signature in human breast cancer |
| Q35538902 | Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility |
| Q37269261 | Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes |
| Q35025741 | Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. |
| Q92351830 | Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations |
| Q28273187 | Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome |
| Q35187831 | Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer? |
| Q89533213 | Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer |
| Q36545168 | Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs |
| Q34558758 | Dual roles for immune metagenes in breast cancer prognosis and therapy prediction |
| Q33878879 | ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss |
| Q54196117 | ESPL1 is a candidate oncogene of luminal B breast cancers. |
| Q61807139 | EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival |
| Q33947907 | Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer |
| Q35626576 | Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers |
| Q37480166 | Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. |
| Q37518671 | Engineered reversal of drug resistance in cancer cells--metastases suppressor factors as change agents. |
| Q28539113 | Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A |
| Q35620990 | Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs |
| Q36504123 | Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis |
| Q47137308 | Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study |
| Q42450983 | Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers |
| Q36397942 | Estrogen receptor prevents p53-dependent apoptosis in breast cancer |
| Q38461102 | Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression |
| Q35503492 | Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value |
| Q92455774 | Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer |
| Q30491493 | Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer |
| Q35677519 | Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis |
| Q36828220 | Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer |
| Q34077048 | Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers |
| Q37328021 | Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer: A systematic review and meta-analysis |
| Q37361137 | Expression profiling of ion channel genes predicts clinical outcome in breast cancer |
| Q34344405 | Expression profiling of mitochondrial voltage-dependent anion channel-1 associated genes predicts recurrence-free survival in human carcinomas |
| Q61448092 | FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier |
| Q36786443 | FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition |
| Q99727476 | FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction |
| Q38835370 | Fatty acid metabolism in breast cancer subtypes |
| Q58793433 | Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers |
| Q92921171 | Flexible Data Trimming Improves Performance of Global Machine Learning Methods in Omics-Based Personalized Oncology |
| Q33768293 | Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer |
| Q64076657 | Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER- Breast Cancer |
| Q64137817 | Gene expression in triple-negative breast cancer in relation to survival |
| Q37958156 | Gene expression profiling in breast cancer: classification, prognostication, and prediction |
| Q38421414 | Gene expression-based prognostic and predictive tools in breast cancer |
| Q37225371 | Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes |
| Q35849104 | Gene-expression signature functional annotation of breast cancer tumours in function of age |
| Q36287371 | Genetic polymorphisms and plasma levels of BCL11A contribute to the development of laryngeal squamous cell carcinoma |
| Q84289417 | Genetics: the crystal ball clears for breast cancer therapy? |
| Q50083199 | Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies |
| Q34199428 | Genome-driven integrated classification of breast cancer validated in over 7,500 samples |
| Q34670804 | Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity |
| Q64104320 | Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy |
| Q29248638 | Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer |
| Q60908056 | Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer |
| Q54481772 | Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. |
| Q41479168 | Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. |
| Q38835169 | Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning |
| Q37065194 | HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer |
| Q55384044 | Harnessing synthetic lethality to predict the response to cancer treatment. |
| Q51427443 | Hepatocyte nuclear factor 1 beta induces transformation and epithelial-to-mesenchymal transition. |
| Q38965383 | High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF-β-dependent epithelial-mesenchymal transition in breast cancer |
| Q37316603 | Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer |
| Q37190152 | Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors |
| Q34717946 | Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression |
| Q64080807 | Human Mitotic Centromere-Associated Kinesin Is Targeted by MicroRNA 485-5p/181c and Prognosticates Poor Survivability of Breast Cancer |
| Q91910743 | Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy |
| Q38853361 | Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers |
| Q36473360 | Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors |
| Q30990059 | IDEA: Integrated Drug Expression Analysis-Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates |
| Q36382215 | IPF-LASSO: Integrative L1-Penalized Regression with Penalty Factors for Prediction Based on Multi-Omics Data. |
| Q39175273 | Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces. |
| Q47327357 | Identification of cancer genes that are independent of dominant proliferation and lineage programs |
| Q36173419 | Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer |
| Q36847243 | Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer |
| Q33837764 | Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration |
| Q37732220 | Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy |
| Q57082684 | Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts |
| Q37214212 | Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis |
| Q31052319 | Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example |
| Q35892045 | Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative |
| Q88573696 | Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-αVβ5 axis |
| Q89143446 | Inhibition of epithelial cell migration and Src/FAK signaling by SIRT3 |
| Q36967938 | Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer |
| Q55711788 | Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses. |
| Q37317612 | Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease |
| Q30837398 | Investigating the prediction ability of survival models based on both clinical and omics data: two case studies |
| Q34476337 | Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? |
| Q47719898 | Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. |
| Q89700992 | LIN9 and NEK2 are core regulators of mitotic fidelity that can be therapeutically targeted to overcome taxane resistance |
| Q33572318 | LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer |
| Q37055054 | Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer |
| Q64997211 | LncRNA Profile Study Reveals a Three-LncRNA Signature Associated With the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer. |
| Q60923339 | Loss of ABAT-Mediated GABAergic System Promotes Basal-Like Breast Cancer Progression by Activating Ca-NFAT1 Axis |
| Q92501708 | Loss of PICH promotes chromosome instability and cell death in triple-negative breast cancer |
| Q42507631 | Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. |
| Q35020412 | Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy |
| Q100464555 | M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer |
| Q90476375 | MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer |
| Q59329098 | ME1 promotes basal-like breast cancer progression and associates with poor prognosis |
| Q35719862 | MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence |
| Q54977971 | MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells. |
| Q33762222 | MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. |
| Q52742033 | MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. |
| Q34664059 | Mammary glands exhibit molecular laterality and undergo left-right asymmetric ductal epithelial growth in MMTV-cNeu mice. |
| Q35828467 | Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies |
| Q33555064 | Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer |
| Q64891091 | Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. |
| Q91868553 | Metabolic enzymes expressed by cancer cells impact the immune infiltrate |
| Q35634563 | Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins. |
| Q42464523 | Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer |
| Q55084135 | Methylation-to-Expression Feature Models of Breast Cancer Accurately Predict Overall Survival, Distant-Recurrence Free Survival, and Pathologic Complete Response in Multiple Cohorts. |
| Q36157026 | MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. |
| Q35857671 | MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene |
| Q36630430 | Molecular characterization of basal-like and non-basal-like triple-negative breast cancer |
| Q46131870 | Molecular classification of triple-negative tumors |
| Q35799667 | Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer |
| Q38236904 | Molecular markers for breast cancer diagnosis, prognosis and targeted therapy |
| Q34374191 | Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes |
| Q35018599 | Multigene prognostic tests in breast cancer: past, present, future |
| Q92880415 | Multigene signatures of responses to chemotherapy derived by biochemically-inspired machine learning |
| Q33632205 | NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth |
| Q38876050 | Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers |
| Q51320601 | Neoadjuvant therapy for ER-positive breast cancers. |
| Q45140936 | Neoadjuvant treatment of breast cancer. |
| Q35429810 | Nomogram for predicting breast conservation after neoadjuvant chemotherapy |
| Q53685190 | Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. |
| Q48300371 | Notch3 negatively regulates chemoresistance in breast cancers. |
| Q92413979 | Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients |
| Q91943338 | Nuclear translocation of PLSCR1 activates STAT1 signaling in basal-like breast cancer |
| Q92781335 | Nup93 regulates breast tumor growth by modulating cell proliferation and actin cytoskeleton remodeling |
| Q33567263 | Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer |
| Q92757615 | On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer |
| Q52877983 | Overexpression of Ran GTPase Components Regulating Nuclear Export, but not Mitotic Spindle Assembly, Marks Chromosome Instability and Poor Prognosis in Breast Cancer. |
| Q42722444 | Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors |
| Q97418214 | PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients |
| Q37686796 | PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression |
| Q64056472 | Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer |
| Q36212421 | Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. |
| Q37679039 | Personalized chemotherapy selection for breast cancer using gene expression profiles |
| Q34608577 | Personalized medicine and cancer |
| Q39374969 | Personalized therapy for breast cancer: a dream or a reality? |
| Q64238567 | Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America |
| Q42217265 | Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning. |
| Q37187379 | Predicting drug responsiveness in human cancers using genetically engineered mice. |
| Q34354538 | Predicting response and survival in chemotherapy-treated triple-negative breast cancer. |
| Q60912249 | Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning |
| Q33692905 | Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance |
| Q34547261 | Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis |
| Q104617805 | Pregnancy-specific glycoprotein 9 acts as both a transcriptional target and a regulator of the canonical TGF-β/Smad signaling to drive breast cancer progression |
| Q38059133 | Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. |
| Q47095948 | Prognostic genes of breast cancer revealed by gene co-expression network analysis |
| Q36819993 | Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer |
| Q44966169 | Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer |
| Q35620241 | RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer |
| Q37244377 | Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients |
| Q44283854 | Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer |
| Q38747404 | Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). |
| Q91987382 | Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets |
| Q36054418 | Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. |
| Q51049666 | Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures. |
| Q35856517 | Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes |
| Q37101303 | Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features |
| Q33659361 | Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population |
| Q36383626 | Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy |
| Q38889500 | Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer |
| Q50892020 | SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. |
| Q64972977 | SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. |
| Q36934463 | SGK3 is associated with estrogen receptor expression in breast cancer |
| Q40007032 | SNRFCB: sub-network based random forest classifier for predicting chemotherapy benefit on survival for cancer treatment |
| Q39677335 | SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. |
| Q35775570 | Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response |
| Q52621007 | Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy. |
| Q33884798 | Spectral clustering using Nyström approximation for the accurate identification of cancer molecular subtypes |
| Q34339885 | Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer |
| Q47141857 | Super-delta: a new differential gene expression analysis procedure with robust data normalization |
| Q37992692 | Surgical considerations in patients receiving neoadjuvant systemic therapy |
| Q90168508 | Synaptic proximity enables NMDAR signalling to promote brain metastasis |
| Q35604047 | Systematic identification of regulatory elements in conserved 3' UTRs of human transcripts |
| Q37618855 | Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers |
| Q36140934 | Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival |
| Q35932609 | Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer. |
| Q39030842 | TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. |
| Q50847430 | Targeting Lyn regulates Snail family shuttling and inhibits metastasis. |
| Q41233155 | Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. |
| Q84959885 | Test may help predict chemotherapy response and survival in breast cancer |
| Q39350574 | Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. |
| Q33630465 | The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients |
| Q37510518 | The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. |
| Q37022393 | The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression |
| Q37189626 | The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition |
| Q39175548 | The molecular basis of breast cancer pathological phenotypes |
| Q92357790 | The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression |
| Q36849660 | The potential for liquid biopsies in the precision medical treatment of breast cancer |
| Q35036920 | The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context |
| Q38671548 | The residual-based predictiveness curve: A visual tool to assess the performance of prediction models. |
| Q38321134 | The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. |
| Q90484944 | The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype |
| Q34324403 | Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4. |
| Q35740145 | Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy |
| Q55518016 | Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance. |
| Q35000651 | Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer |
| Q52587869 | Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. |
| Q59238285 | Vascular proliferation is a prognostic factor in breast cancer |
| Q63884112 | Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanisms |
| Q57009832 | Visualization of Patient Samples by Dimensionality Reduction of Genome-Wide Measurements |
| Q37721627 | WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel |
| Q55517228 | miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking. |
| Q26744071 | multiClust: An R-package for Identifying Biologically Relevant Clusters in Cancer Transcriptome Profiles |
Search more.